25 completed, 3 terminated, 2 recruiting, 2 withdrawn. 34 Phase 2, 9 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 25, Terminated 3, Recruiting 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 9 | Completed 8, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
Follow Rickets: new trials by email Literature Review of Rickets trials Research Report on Rickets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial Low-dose Colchicine at 0.5mg daily, Usual Care - Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-30 | 2026-11-04 |
| Activated Charcoal Use in Chronic Kidney Disease Patients Activated Charcoal, Phosphate Binders - End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis | Phase 2 | Recruiting | Mansoura University | 40 | 2025-08-01 | 2025-08-08 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-11-06 |
| DePTH: De-emphasize PTH Oral calcitriol with cinacalcet rescue, IV activated vitamin D - Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 2 | Active not recruiting | University of Washington | 90 | 2024-03-11 | 2025-06-02 |
| Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Burosumab - Fibrous Dysplasia Of Bone | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 12 | 2022-12-07 | 2026-02-02 |
| Effectiveness of Vitamin C Supplementation in Treatment of Rickets Vit C - Nutritional Rickets, Bone Turnover Rate Disorder | Phase 2 / Phase 3 | Completed | Cairo University | 88 | 2022-03-01 | 2023-03-08 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients Denosumab Inj 60 mg/ml, Placebo - Osteoporosis, Renal Osteodystrophy | Phase 2 | Terminated | Thomas Nickolas, MD MS | 8 | 2020-01-16 | 2024-07-25 |
| Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia 68Ga-DOTATATE PET/CT - Osteomalacia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 18 | 2019-01-31 | 2025-04-30 |
| The Effect of Etelcalcetide on CKD-MBD Etelcalcetide - Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy | Phase 2 | Completed | Thomas Nickolas, MD MS | 22 | 2018-09-06 | 2023-09-21 |
| The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L) - Endstage Renal Disease | Phase 2 | Completed | Iain Bressendorff | 59 | 2016-12-01 | 2018-06-06 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) KRN23 - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 20 | 2015-01-30 | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 52 | 2014-07-02 | 2024-05-06 |
| Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy Yougui granules, Zuogui granules, Yougui granules placebo - Renal Insufficiency, Chronic, Renal Osteodystrophy | Phase 2 | Withdrawn | Bing Shu | 2012-08-01 | 2017-05-08 | |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism Etelcalcetide - Secondary Hyperparathyroidism | Phase 2 | Terminated | KAI Pharmaceuticals | 30 | 2012-03-01 | 2017-04-13 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 23 | 2012-02-01 | 2024-06-18 |
| Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder Etelcalcetide - Secondary Hyperparathyroidism | Phase 2 | Completed | KAI Pharmaceuticals | 37 | 2011-12-05 | 2017-04-11 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 29 | 2011-04-01 | 2024-06-18 |
| Vitamin D Supplementation in Breastfeeding Women Vitamin D3 - Vitamin D Deficiency, Rickets | Phase 2 / Phase 3 | Completed | Mayo Clinic | 80 | 2010-12-01 | 2013-04-30 |
Showing 20 of 34. Sign in to see all of them.
Chronic Kidney Disease-Mineral and Bone Disorder (13) · Osteomalacia (10) · Bone Diseases (9) · Familial Hypophosphatemic Rickets (8) · Hypophosphatasia (7) · Kidney Failure, Chronic (4) · Hyperparathyroidism, Secondary (3) · Vitamin D Deficiency (3) · Bone Diseases, Metabolic (2) · Kidney Diseases (2) · Osteoporosis (2) · Rare Diseases (2) · Renal Insufficiency, Chronic (2) · Vascular Calcification (2)
Avitaminosis (34) · Calcium Metabolism Disorders (34) · Deficiency Diseases (34) · Malnutrition (34) · Nutrition Disorders (34) · Nutritional and Metabolic Diseases (34) · Metabolic Diseases (33) · Musculoskeletal Diseases (33) · Bone Diseases, Metabolic (32) · Vitamin D Deficiency (31) · Bone Diseases (25) · Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Male Urogenital Diseases (21)
asfotase alfa (7) · burosumab (7) · Calcitriol (4) · etelcalcetide hydrochloride (3) · Cholecalciferol (2) · Growth Hormone (2) · 1 alpha-hydroxyergocalciferol (1) · Calcium (1) · Calcium Carbonate (1) · Charcoal (1) · Cinacalcet (1) · Denosumab (1) · Niacinamide (1) · Sevelamer (1)
Alexion Pharmaceuticals, Inc. (7) · Kyowa Kirin Co., Ltd. (3) · Kyowa Kirin, Inc. (3) · KAI Pharmaceuticals (2) · Mayo Clinic (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Thomas Nickolas, MD MS (2) · Amgen (1) · Bicetre Hospital (1) · Bing Shu (1) · Cairo University (1) · Iain Bressendorff (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · Mansoura University (1) · National Center for Research Resources (NCRR) (1)
United States (22) · Canada (8) · United Kingdom (5) · France (4) · Spain (3) · Egypt (2) · Germany (2) · Italy (2) · United Arab Emirates (2) · Australia (1) · Austria (1) · China (1) · Denmark (1) · Japan (1) · Netherlands (1)
Amy Zhang, PhD (2) · Thomas Nickolas, MD, MS (2) · Alison M Boyce, M.D. (1) · Daniel O Young, MD (1) · Fatina Fadel, Prof (1) · Gregory Bell, MD (1) · Isidro B Salusky, MD (1) · Isidro B. Salusky (1) · Jing Chen, MD (1) · M D (1) · Matthew Drake, MD (1) · Michael P. Whyte, MD (1)
PMID 26529632, PMID 32417537, PMID 32762706, PMID 25919461, PMID 27699270, PMID 32721016, PMID 39151033, PMID 40576086, PMID 18397701, PMID 19244376, PMID 19776051, PMID 22397652, PMID 24120120, PMID 24290111, PMID 26073451, PMID 28822957, PMID 29486367, PMID 29791829, PMID 30558909, PMID 30638856, PMID 30811537, PMID 30969260, PMID 34636899, PMID 36072994, PMID 37574661, PMID 42044650
K23DK136930 (1)